SPAK kinase inhibitors as neuroprotective agents

US10995061B2 · kind B2 · utility

Assignees

• United States Government as represented by the Department of Veterans Affairs · US
• University of Pittsburgh—Of the Commonwealth System of Higher Education · US
• XIAMEN UNIVERSITY · CN
• UNIVERSITY OF EXETER · GB

Inventors

• Dandan Sun · Hefei, CN
• Xianming Deng · Fujian, CN
• Jinwei Zhang · Ningbo City, CN
• Mohammad Iqbal Hossain Bhuiyan · Pittsburgh, US
• Bradley J. Molyneaux · Pittsburgh, US

Key dates

• Filing date: Sep 30, 2019
• Grant date: May 4, 2021
• Expiry date: Sep 30, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C323/62
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure is concerned with N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)benzamide compounds that are capable of inhibiting SPAK kinase function, methods of treating hypoxic brain injuries due to, for example, ischemic stroke. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.